Mini-reviewThe underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer

- Introduce the role of miRNAs and lncRNAs in the chemoresistance of pancreatic cancer, including their expression level, targets, biological functions and the regulation of chemoresistance.
- Discuss the potential clinical application of miRNAs and lncRNAs in the treatment of pancreatic cancer.
- Introduce the mechanism of miRNAs and lncRNAs in the chemoresistance of pancreatic cancer.

Pancreatic cancer, which is often asymptomatic, is currently one of the most common causes of cancer-related death. This phenomenon is most likely due to a lack of early diagnosis, a high metastasis rate and a disappointing chemotherapy outcome. Thus, improving treatment outcomes by overcoming chemotherapy resistance may be a useful strategy in pancreatic cancer. Various underlying mechanisms involved in the chemoresistance of pancreatic cancer have been investigated. Notably, non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play a pivotal role in regulating sensitivity to chemotherapy in pancreatic cancer. In this review, we highlight recent evidence regarding the role of miRNAs and lncRNAs in the chemoresistance of pancreatic cancer, including their expression levels, targets, biological functions and the regulation of chemoresistance, and discuss the potential clinical application of miRNAs and lncRNAs in the treatment of pancreatic cancer.